Department of Medical Biochemistry, Medical Faculty of Tekirdağ Namık Kemal University, Tekirdağ, Turkey.
İnfectious Diseases and Clinical Microbiology Department, Çorlu State Hospital Tekirdağ, Tekirdağ, Turkey.
Niger J Clin Pract. 2022 Sep;25(9):1418-1423. doi: 10.4103/njcp.njcp_1633_21.
In coronavirus disease 2019 (COVID-19) caused by SARSCoV2 viruses, coagulation abnormalities are strongly correlated between disease severity and mortality risk.
The aim was to search for new indices to determine mortality risk. Fibrinogen times D-dimer to albumin times platelet ratio calculated with the formula (FDAPR index: ((Fibrinogen × D-dimer)/(Albumin × Platelet)) investigated as a mortality marker in COVID-19 patients. The hospitalization data of 1124 patients were analyzed from the electronic archive system. Hemogram, coagulation, and inflammatory markers were investigated in the study group.
All statistical analyses like the student t-test, Mann-Whitney U, Kaplan-Meier, and Cox hazard ratio, were performed with the SPSS 22.0 program.
Prothrombin time was prolonged significantly in patients (P < 0.05) compared to healthy subjects (n = 30). D-dimer and fibrinogen were high, and albumin and platelet counts were low in COVID-19 patients (all, P < 0.001). When the data of 224 non-survivors and 900 survived patients were compared, D-dimer and fibrinogen were higher, and albumin and platelet lower (all, P < 0.001) compared to mild and severe patients. At the cut-off value of 0.49, the FDAPR index was performed with 89.1% sensitivity and 88.6% specificity. FDAPR index had the highest mortality predictive power (P < 0.01; HR = 5.366; 95% CI; 1.729-16.654).
This study revealed that the FDAPR index could be used as a mortality marker of COVID-19 disease.
在由 SARSCoV2 病毒引起的 2019 年冠状病毒病（COVID-19）中，凝血异常与疾病严重程度和死亡风险密切相关。
旨在寻找新的指标来确定死亡风险。使用公式计算的纤维蛋白原时间与 D-二聚体除以白蛋白与血小板的比值（FDAPR 指数：（纤维蛋白原×D-二聚体）/（白蛋白×血小板））被研究作为 COVID-19 患者的死亡率标志物。从电子档案系统中分析了 1124 名患者的住院数据。在研究组中研究了血液学、凝血和炎症标志物。
使用 SPSS 22.0 程序进行所有统计分析，如学生 t 检验、Mann-Whitney U、Kaplan-Meier 和 Cox 风险比。
与健康受试者（n=30）相比，患者的凝血酶原时间明显延长（P<0.05）。COVID-19 患者的 D-二聚体和纤维蛋白原较高，白蛋白和血小板计数较低（均 P<0.001）。当比较 224 名非幸存者和 900 名存活患者的数据时，与轻症和重症患者相比，D-二聚体和纤维蛋白原较高，白蛋白和血小板较低（均 P<0.001）。FDAPR 指数的截断值为 0.49，其灵敏度为 89.1%，特异性为 88.6%。FDAPR 指数具有最高的死亡率预测能力（P<0.01；HR=5.366；95%CI；1.729-16.654）。
本研究表明，FDAPR 指数可作为 COVID-19 疾病的死亡率标志物。
